Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014 PowerPoint presentation | free to download - id: 72a39b-MjZjM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014

Description:

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Browse full report @ – PowerPoint PPT presentation

Number of Views:11

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014


1
Primary Biliary Cirrhosis - Pipeline Review, H2
2014
Pharmaceutical and Healthcare Market Research
Report
2
Summary
  • Primary Biliary Cirrhosis - Pipeline Review, H2
    2014, provides an overview of the Primary Biliary
    Cirrhosiss therapeutic pipeline.
  • This report provides comprehensive information
    on the therapeutic development for Primary
    Biliary Cirrhosis, complete with comparative
    analysis at various stages, therapeutics
    assessment by drug target, mechanism of action
    (MoA), route of administration (RoA) and molecule
    type, along with latest updates, and featured
    news and press releases. It also reviews key
    players involved in the therapeutic development
    for Primary Biliary Cirrhosis and special
    features on late-stage and discontinued
    projects.Global Markets Directs report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team. Drug
    profiles/records featured in the report undergoes
    periodic updation following a stringent set of
    processes that ensures that all the profiles are
    updated with the latest set of information.

3
Scope
  • The report provides a snapshot of the global
    therapeutic landscape of Primary Biliary
    Cirrhosis- The report reviews key pipeline
    products under drug profile section which
    includes, product description, MoA and RD brief,
    licensing and collaboration details other
    developmental activities - The report reviews
    key players involved in the therapeutics
    development for Primary Biliary Cirrhosis and
    enlists all their major and minor projects- The
    report summarizes all the dormant and
    discontinued pipeline projects - A review of the
    Primary Biliary Cirrhosis products under
    development by companies and universities/research
    institutes based on information derived from
    company and industry-specific sources- Pipeline
    products coverage based on various stages of
    development ranging from pre-registration till
    discovery and undisclosed stages- A detailed
    assessment of monotherapy and combination therapy
    pipeline projects
  • - Coverage of the Primary Biliary Cirrhosis
    pipeline on the basis of target, MoA, route of
    administration and molecule type- Latest news
    and deals relating related to pipeline products

4
Reasons to buy
  • - Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies- Identify
    emerging players with potentially strong product
    portfolio and create effective counter-strategies
    to gain competitive advantage- Develop strategic
    initiatives by understanding the focus areas of
    leading companies- Identify and understand
    important and diverse types of therapeutics under
    development for Primary Biliary Cirrhosis- Plan
    mergers and acquisitions effectively by
    identifying key players of the most promising
    pipeline- Devise corrective measures for
    pipeline projects by understanding Primary
    Biliary Cirrhosis pipeline depth and focus of
    Indication therapeutics- Develop and design
    in-licensing and out-licensing strategies by
    identifying prospective partners with the most
    attractive projects to enhance and expand
    business potential and Scope- Modify the
    therapeutic portfolio by identifying discontinued
    projects and understanding the factors that drove
    them from pipeline

5
Table of Content
  • Global Markets Direct Report Coverage 6Primary
    Biliary Cirrhosis Overview 7Therapeutics
    Development 8Pipeline Products for Primary
    Biliary Cirrhosis - Overview 8Pipeline Products
    for Primary Biliary Cirrhosis - Comparative
    Analysis 9Primary Biliary Cirrhosis -
    Therapeutics under Development by Companies
    10Primary Biliary Cirrhosis - Pipeline Products
    Glance 12Late Stage Products 12Clinical Stage
    Products 13Early Stage Products 14Primary
    Biliary Cirrhosis - Products under Development by
    Companies 15Primary Biliary Cirrhosis -
    Companies Involved in Therapeutics Development
    16AlbireoPharma 16Dr. Falk Pharma GmbH
    17GlaxoSmithKline plc 18Intercept
    Pharmaceuticals, Inc. 19Johnson Johnson 20

6
List of Tables
  • Number of Products under Development for Primary
    Biliary Cirrhosis, H2 2014 8Number of Products
    under Development for Primary Biliary Cirrhosis -
    Comparative Analysis, H2 2014 9Number of
    Products under Development by Companies, H2 2014
    11Comparative Analysis by Late Stage
    Development, H2 2014 12Comparative Analysis by
    Clinical Stage Development, H2 2014
    13Comparative Analysis by Early Stage
    Development, H2 2014 14Products under
    Development by Companies, H2 2014 15Primary
    Biliary Cirrhosis - Pipeline by AlbireoPharma, H2
    2014 16Primary Biliary Cirrhosis - Pipeline by
    Dr. Falk Pharma GmbH, H2 2014 17Primary Biliary
    Cirrhosis - Pipeline by GlaxoSmithKline plc, H2
    2014 18Primary Biliary Cirrhosis - Pipeline by
    Intercept Pharmaceuticals, Inc., H2 2014
    19Primary Biliary Cirrhosis - Pipeline by
    Johnson Johnson, H2 2014 20Primary Biliary
    Cirrhosis - Pipeline by MediGene AG, H2 2014
    21Primary Biliary Cirrhosis - Pipeline by NGM
    Biopharmaceuticals, Inc., H2 2014 22Primary
    Biliary Cirrhosis - Pipeline by Shire Plc, H2
    2014 23Primary Biliary Cirrhosis - Pipeline by
    Virobay Inc., H2 2014 24

7
List of Figures
  • Number of Products under Development for Primary
    Biliary Cirrhosis, H2 2014 8Number of Products
    under Development for Primary Biliary Cirrhosis -
    Comparative Analysis, H2 2014 9Number of
    Products under Development by Companies, H2 2014
    10Comparative Analysis by Clinical Stage
    Development, H2 2014 13Assessment by Monotherapy
    Products, H2 2014 25Number of Products by Top 10
    Targets, H2 2014 26Number of Products by Stage
    and Top 10 Targets, H2 2014 27Number of Products
    by Top 10 Mechanism of Actions, H2 2014 28Number
    of Products by Stage and Top 10 Mechanism of
    Actions, H2 2014 29Number of Products by Top 10
    Routes of Administration, H2 2014 30Number of
    Products by Stage and Top 10 Routes of
    Administration, H2 2014 31Number of Products by
    Top 10 Molecule Types, H2 2014 32Number of
    Products by Stage and Top 10 Molecule Types, H2
    2014 33

8
Related Reports
  • Fabry Disease-Pipeline Insights, 2015
  • Ocular Hypertension-Pipeline Insights, 2015
  • Fallopian Tube Cancer-Pipeline Insights, 2015
  • Ocular Inflammation-Pipeline Insights, 2015
  • Familial Adenomatous Polyposis Coli-Pipeline
    Insights, 2015
  • Ocular Pain-Pipeline Insights, 2015
  • Oligodendroglioma-Pipeline Insights, 2015
  • Familial Chylomicronemia (Type I
    Hyperlipoproteinemia)-Pipeline Insights, 2015

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
About PowerShow.com